Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Trial Profile

Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Completed
Phase of Trial: Phase III

Latest Information Update: 28 May 2018

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions
  • Acronyms TIRCON-EXT
  • Sponsors ApoPharma
  • Most Recent Events

    • 23 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 17 Apr 2018 This trial has been completed in Germany (end date: 16 Mar 2018) , according to European Clinical Trials Database.
    • 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top